Y
ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Oncology · Lancet · 2026-10-26

In 299 patients with mismatch repair-deficient advanced or recurrent endometrial cancer, first-line pembrolizumab beat carboplatin-paclitaxel on progression-free survival (median 38·2 vs 8·4 months; HR 0·57); overall survival not significant at interim analysis.

RCTn = 299
Slomovitz et al. First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial
Oncology · J Clin Oncol · 2026-09-24

In 731 patients with untreated advanced HER2-negative gastric/GEJ adenocarcinoma, retlirafusp alfa plus CAPOX improved OS vs placebo plus CAPOX (median 15.8 vs 11.2 months, HR 0.66; CPS ≥5: 16.8 vs 10.4, HR 0.53). Grade ≥3 toxicity similar.

RCTn = 731
Peng et al. First-Line Retlirafusp Alfa Plus Chemotherapy for Human Epidermal Growth Factor Receptor 2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Randomized, Double-Blind, Phase III Study (RELIGHT)
Oncology · J Clin Oncol · 2026-09-09

Secondary analysis of a phase II trial of preoperative radiotherapy with or without pembrolizumab in 106 patients with localised soft tissue sarcoma: personalised ctDNA was found in 85% at baseline and levels independently predicted survival.

Secondary analysisn = 106
Subramanian et al. Personalized Circulating Tumor DNA Analysis for Predicting Outcomes and Tracking Response to Radiotherapy and Pembrolizumab in Localized Sarcomas: Analysis of the SU2C-SARC032 Trial
Oncology · Lancet Oncol · 2026-09-07

In 1367 women with advanced BRCA non-mutated ovarian cancer, pembrolizumab-chemotherapy then pembrolizumab-olaparib maintenance improved progression-free survival vs chemotherapy (ITT HR 0·68 interim, 0·71 final); pembrolizumab alone did not (CPS≥10 HR 0·95).

RCTn = 1,367
Vergote et al. Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial
Oncology · J Clin Oncol · 2026-09-03

Updated analysis of a phase II trial in 436 patients with unfavourable cancer of unknown primary controlled after induction chemotherapy: molecularly guided therapy improved median PFS vs continued chemotherapy (6.1 vs 4.4 months; HR 0.75); OS gain non-significant (HR 0.79).

RCTn = 436
Krämer et al. Molecularly Guided Therapy Versus Continued Chemotherapy in Unfavorable Cancer of Unknown Primary: Updated Efficacy and Safety From the Randomized, Phase II CUPISCO Study
Oncology · Lancet Oncol · 2026-09-01

In embolisation-eligible hepatocellular carcinoma, durvalumab plus tremelimumab plus lenvatinib with TACE improved median PFS vs TACE alone (13·0 vs 9·8 months; HR 0·70); overall survival did not differ significantly (HR 0·84; p=0·18).

RCTn = 760
Kudo et al. Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study
Oncology · Lancet · 2026-08-22

In 201 patients with HCC and macrovascular invasion stable or responding on atezolizumab-bevacizumab, resection lengthened median time to treatment failure vs maintenance (20·4 vs 11·8 months; HR 0·60); grade 3–4 treatment-related events 39% vs 21%, 2 treatment-related deaths.

RCTn = 201
Sun et al. Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial
Oncology · Ann Oncol · 2026-08-21

After chemoradiotherapy for unresectable oesophageal SCC, atezolizumab plus tiragolumab did not improve PFS (HR 0.82) or OS (HR 0.91) vs placebo, missing the primary endpoint. Atezolizumab alone had longer OS (HR 0.69; descriptive P). Treatment-related AEs: 74.8%, 65.2%, 55.4%.

RCTn = 760
Xu et al. Atezolizumab with or without tiragolumab in unresectable esophageal squamous-cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study

Sign in to react

Enter your email and we send a one-time link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.